Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 3Other hematologic neoplasm 3Lymphoid 2Gynecologic 2Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Leukemia 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 229fludarabine phosphate 206fludarabine 163Busulfan 150Mycophenolic Acid 135Tacrolimus 133Whole-Body Irradiation 132Peripheral Blood Stem Cell Transplantation 121Cytarabine 101Azacitidine 100Antilymphocyte Serum 98Melphalan 96Cyclosporine 96Methotrexate 87Imatinib Mesylate 87Filgrastim 85Decitabine 66Granulocyte Colony-Stimulating Factor 60Thiotepa 57venetoclax 53Stem Cell Transplantation 53thymoglobulin 51Radiotherapy 49Cord Blood Stem Cell Transplantation 42nilotinib 40Clofarabine 38Dasatinib 37Methylprednisolone 36ruxolitinib 35Etoposide 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × 7-hydroxystaurosporine × Myeloid × Clear all
NCT00004263 2012-07-30

Cytarabine and UCN-01 in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Myelodysplastic Syndrome

M.D. Anderson Cancer Center

Phase 1 Completed
16 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡